LANSING, Mich., June 7, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, announced today that it has launched the new CelluSmart technology from Megazyme® by Neogen for the measurement of cellulosic ethanol from biofuel production.In creating this industry-first technology, Neogen improved upon the previous National Renewable Energy Laboratory (NREL) procedure, introducing a yeast-degrading cocktail (YDC). With these improvements, CelluSmart allows the ...

LANSING, Mich., June 5, 2024 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, announced today that the Company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, Florida, on Wednesday, June 12, 2024.About NeogenNeogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed com ...

LANSING, Mich., May 30, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, announced today that the Company will participate in the 44th Annual William Blair Growth Stock Conference in Chicago, Illinois, on Tuesday, June 4, 2024. John Adent, Neogen's President and Chief Executive Officer, will present at 8:00 a.m. Central Time. Presentation materials will be posted to the Neogen Investor Relations website on the morning of June 4. To access them, along wi ...

Neogen's (NEOG) vast international trade continues to be impacted by global macroeconomic issues. Also, a tough competitive landscape weighs on the stock. Neogen currently carries a Zacks Rank #4 (Sell).Neogen’s business continues to be impacted by the ongoing complex geopolitical situation globally, which is driving a higher-than-anticipated increase in expenses in terms of raw materials and freight. It is also likely to have broader economic impacts and security concerns, affecting the company’s business ...

LANSING, Mich., May 8, 2024 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today that the Company will participate in the Bank of America 2024 Health Care Conference in Las Vegas, Nevada, on Wednesday, May 15, 2024. About Neogen Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock ...

LANSING, Mich., May 7, 2024 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today that the Company will participate in the 2024 RBC Capital Markets Global Healthcare Conference in New York, New York, on Tuesday, May 14, 2024.John Adent, Neogen's Chief Executive Officer, will present at 4:05 PM Eastern Time.To access the webcast and presentation materials, please visit the Events & Presentations section of the Neogen Investor Relations website at neogen.com/investor-relations/events-presentations ...

LANSING, Mich., May 1, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) is celebrating 40 years of Petrifilm, the innovation that changed how microbiologists around the world perform indicator testing. Petrifilm®: A history of innovation and success. "In the food safety industry, Petrifilm is recognized as a true game-changer," said John Adent, Neogen's President and CEO. "To have this groundbreaking solution as part of the Neogen portfolio showcases our commitment to providing best-in-class solu ...

LANSING, Mich., April 30, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG), a worldwide leader in innovative solutions that help the food and beverage industries ensure safety and quality in their products, announced today the launch of the new Neogen Molecular Detection Assay 2 – Salmonella Enteritidis/Salmonella Typhimurium (MDA2SEST). The product joins several other next-generation assays, including Salmonella, E. coli O157 (including H7), Listeria and Listeria monocytogenes, Campylobacter, STEC g ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 29, 2024. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17988 Neogen Corporation (Exact name of registrant as specified in its charter) Michigan 38-2367843 (State or other jurisdict ...

财务数据和关键指标变化 - 第三季度收入为2.29亿美元,扣除汇率、收购和停产产品线的影响,核心收入同比增长超6% [24] - 毛利率为51.1%,同比增加160个基点,主要由于前3M产品(尤其是Petrifilm)销售的恢复 [32] - 调整后EBITDA为5300万美元,调整后EBITDA利润率为23%,同比下降50个基点,主要由于运营费用增长超过毛利改善 [33][34][35][36] - 调整后净收入和调整后每股收益基本持平上年同期,分别为2600万美元和0.12美元,主要由于与ERP实施相关的折旧费用增加 [37] - 公司现金头寸为1.68亿美元,受到整合资本支出和从3M分销网络退出导致的更多原材料库存采购的影响 [38] 各条业务线数据和关键指标变化 食品安全业务 - 收入为1.58亿美元,同比增长4%,核心收入增长近6% [25] - 指示剂检测、培养基和其他产品类别实现两位数增长,主要受益于Petrifilm和样品处理产品线在北美和欧洲的强劲表现 [25] - 天然毒素和过敏原类别,过敏原中坚果检测试剂盒增长,但天然毒素下降,主要由于产品供应受限 [26] - 细菌和一般卫生类别,微生物和一般卫生有所增长,但病原体下降,主要由于向拉丁美洲和亚洲的发货延迟 [26] 动物安全业务 - 收入为7100万美元,核心收入增长7% [27] - 非基因组学销售(主要通过分销商)增长15%,显著好于上一季度,生物安全产品组合、兽医仪器和耗材等主要类别均实现增长 [27][28] - 基因组学业务收入中单位下降,主要由于战略转向大型动物市场,抵消了欧洲和中国奶牛基因组学的增长 [28] 各个市场数据和关键指标变化 - 北美市场核心收入增长高个位数,多个主要产品类别包括Petrifilm、病原体、样品处理、卫生监测、生物安全和兽医仪器均实现强劲增长 [29] - 欧洲市场核心收入增长中个位数,Petrifilm、病原体和样品处理以及基因组学表现良好 [29] - 亚太地区核心收入基本持平,过敏原、生物安全产品和基因组学增长,但病原体和样品处理下降,部分受到供货限制影响 [30] - 拉丁美洲市场核心收入也基本持平,过敏原检测试剂盒、生物安全产品、兽医仪器和基因组学服务增长,但培养基、病原体和样品处理产品出口受限 [30] 公司战略和发展方向及行业竞争 - 公司完成了前3M病原体检测产品线的搬迁和部分样品处理产品线的搬迁,正在建设Petrifilm新生产线 [7][8][9] - 公司在病原体检测和食品质量分析方面持续创新,推出了针对家禽行业的新型分子检测试剂盒,以及可区分生物乙醇原料来源的新型检测方法 [18][20] - 公司认为整合过程中的运营效率问题是暂时的,将努力解决以满足客户需求,并收回失去的客户 [11][17][22][45] - 公司将加快审视业务组合,同时外部市场环境正在改善,食品行业产量和动物安全分销商库存水平均有所好转 [44][45] 管理层对经营环境和未来前景的评论 - 公司认为运营效率问题是暂时的,将努力解决以满足客户需求,并收回失去的客户 [11][17][22][45] - 公司预计2024财年全年收入将在9.1-9.2亿美元之间,调整后EBITDA在2.1-2.15亿美元之间 [40] - 公司表示明年集成资本支出将大幅下降,并有望实现100%自由现金流转化率 [52][43] - 公司认为外部市场环境正在改善,食品行业产量和动物安全分销商库存水平均有所好转 [44][45] 问答环节重要的提问和回答 问题1 **David Westenberg 提问** 询问公司在整合过程中的工资资本和现金流情况 [48][49][50][51][52] **David Naemura 回答** - 公司在第二和第三季度共引入了约4800万美元的3M产成品库存 - 第三季度资本支出中有2300万美元用于整合,全年预计约1亿美元 - 由于整合影响,公司预计全年自由现金流将为负7500万美元左右 [49][50][51][52] 问题2 **Brandon Vazquez 提问** 询问公司在第二和第三季度的运营效率问题是否有所恶化,以及对未来的信心 [62][63][64][65][66][67] **John Adent 回答** - 第三季度未交付订单量与第二季度基本持平,但发货效率有所提升 - 公司正在努力解决SAP系统与仓储系统之间的接口问题,以实现24小时内发货的目标 [67][68][69] - 尽管当前受到一些客户流失,但公司有信心通过改善供应能力,将这些客户重新拉回 [78][79][80] 问题3 **Brandon Vazquez 提问** 询问公司未来的利润率水平和增长潜力 [75][76][77] **John Adent 回答** - 公司认为通过解决当前的运营效率问题,未来仍有能力实现高个位数以上的收入增长和30%以上的EBITDA利润率 - 但时间节点可能需要一些调整,公司正在采取措施来提高效率和盈利能力 [78][79][80]